NET (LOSS) INCOME PER SHARE (Tables)

12 Months Ended

Dec. 31, 2019

Schedule of calculation of basic and diluted earnings per common share

Basic and diluted earnings per common share are calculated as follows (in thousands, except for per share amounts):



	Year ended December 31,
	2019			2018		2017
Basic net income (loss) per share
Net (loss) income	$	(217,201	)	$	36,908	$	(102,496	)
Weighted average common shares outstanding	70,716			63,794		62,702
Basic net (loss) income per share	$	(3.07	)	$	0.58	$	(1.63	)

Diluted net income (loss) per share
Net (loss) income	$	(217,201	)	$	36,908	$	(102,496	)
Weighted average common shares outstanding	70,716			63,794		62,702
Add: effect of dilutive securities	—			414		—
Denominator for diluted income (loss) per share	70,716			64,208		62,702
Diluted net (loss) income per share	$	(3.07	)	$	0.57	$	(1.63	)

Schedule of antidilutive securities excluded from computation of diluted net income (loss) per share

The following table sets forth outstanding potential shares of common stock that are not included in the computation of diluted net income (loss) per share because, to do so would be anti-dilutive (in thousands):



	Year ended December 31,
	2019	2018	2017
2.5% Convertible Notes due 2021	13,895	17,931	17,931
5.0% Convertible Notes due 2024	14,895	—	—
Stock options and equivalents	6,486	3,701	5,618
Total potentially dilutive common shares	35,276	21,632	23,549

Assertio Therapeutics, Inc 10-K